Compound comparison
Tirzepatide vs Semaglutide
Both are incretin-class peptides studied as reference materials in metabolic research. The defining difference is receptor coverage: semaglutide acts on a single receptor (GLP-1), while tirzepatide is a dual agonist that adds the GIP receptor. Supplied for laboratory research use only; not for human or veterinary use.
| Tirzepatide | Semaglutide | |
|---|---|---|
| Compound class | Dual receptor agonist | GLP-1 receptor agonist (mono) |
| Receptor targets | GIP · GLP-1 | GLP-1 |
| Molecular formula | C225H348N48O68 | C187H291N45O59 |
| Molecular weight | ≈ 4813.45 Da | ≈ 4113.58 Da |
| CAS number | 2023788-19-2 | 910463-68-2 |
| Developer | Eli Lilly | Novo Nordisk |
| Primary research area | Incretin / metabolic research | Incretin / metabolic research |
| Format at TagPep | 60 mg lyophilized research vial | Reference only — not stocked |
Molecular data verified against PubChem and published literature. Molecular weights are average values.
Semaglutide acts on the GLP-1 receptor alone. Tirzepatide engages GLP-1 and GIP — the added GIP pathway is what makes it a dual agonist and the main variable researchers compare against semaglutide's single-receptor profile. The triple agonist retatrutide extends the same axis with a third (glucagon) receptor.
Each is an investigational synthetic peptide used as a characterized reference material in metabolic and receptor-signaling research, with identity and reported purity confirmed by batch documentation. For the broader class see the multi-receptor agonist primer and the research-peptide reference table.
Tirzepatide 60 mg — in stock
Dual GIP/GLP-1 · lyophilized research vial with batch documentation
Semaglutide is listed for reference only. Browse the full catalog of stocked research compounds in the shop.
Common questions
What is the difference between tirzepatide and semaglutide?
Receptor coverage. Semaglutide is a single (mono) agonist that acts on the GLP-1 receptor only. Tirzepatide is a dual agonist that engages both GLP-1 and GIP receptors — the added GIP-receptor activity is its distinguishing feature. Both are synthetic incretin-class peptides studied in metabolic research and supplied for laboratory research use only.
Do tirzepatide and semaglutide target the same receptors?
Both target the GLP-1 receptor. Tirzepatide additionally targets the GIP receptor, which is the primary variable researchers compare between the two. Retatrutide extends this further with a third (glucagon) receptor.
Can I buy tirzepatide for research?
Yes. TagPep stocks tirzepatide as a 60 mg lyophilized research vial with batch-specific analytical documentation, for laboratory research use only. Semaglutide is shown here for reference and comparison.
Related comparisons
This comparison is factual reference information for laboratory research and educational use. Both compounds are research materials supplied for laboratory research use only — not for human or veterinary use, consumption, injection, administration, diagnosis, or treatment. No dosing or administration guidance is provided or implied.